Becton, Dickinson and Company (NYSE:BDX) is included among the 15 Best Stocks to Buy for the Long Term. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares. The analyst noted that the company’s MedTech “looks well-positioned on several fronts.” The firm also thinks that ma ...

Wolfe Research upgraded life sciences toolmaker Waters Corporation (WAT) to Outperform from Peer Perform on Wednesday, citing potential tailwinds from its proposed merger with BD's (BDX) Biosciences & Diagnostic Solutions unit. The upgrade comes as Waters (WAT) and Becton, Dickinson ( ...

Core Insights - Becton, Dickinson and Company (BDX) has announced a collaboration with ChemoGLO to enhance hazardous drug contamination testing in healthcare settings, aiming to improve safety for healthcare workers [1][8] Company Developments - The collaboration is a strategic move to strengthen BDX's Medication Delivery Solutions (MDS) business unit within the BD Medical segment [2] - The partnership will integrate BD HD Check System's rapid qualitative results with ChemoGLO's advanced analytical methods, providing comprehensive quantitative reports on hazardous drugs within three to five days [4][5] - BDX's management anticipates that this collaboration will enable quicker identification of contamination risks and enhance understanding of exposure risks [5] Market Performance - Following the announcement, BDX shares increased by nearly 0.1%, with a current market capitalization of $55.54 billion and an earnings yield of 7.7%, surpassing the industry average of 5.8% [3] - Over the past year, BDX shares have decreased by 11.1%, contrasting with an 8% rise in the industry and a 15.3% gain in the S&P 500 [9] Industry Outlook - The global drug screening market is projected to grow from $15.4 billion in 2025 to $52.2 billion in 2034, at a compound annual growth rate (CAGR) of 14.5%, driven by increasing concerns over substance abuse and stricter regulatory requirements [6]

Core Insights - BD and ChemoGLO™ have formed a strategic collaboration to enhance hazardous drug contamination testing in healthcare settings, aiming to improve the safety of healthcare workers [1][2]. Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery, with over 70,000 employees and a presence in nearly every country [4]. - ChemoGLO™ specializes in hazardous drug detection and management solutions, providing accurate measurements of surface contamination levels for over 20 years [5][6]. Collaboration Details - The collaboration combines BD's HD Check System, which provides rapid qualitative results in 10 minutes, with ChemoGLO™'s LC-MS/MS analysis, delivering comprehensive quantitative reports on hazardous drugs within three to five days [2]. - This dual approach allows healthcare facilities to quickly identify contamination and gain deeper insights into exposure risks, reinforcing the commitment to healthcare worker safety [2][3]. Testing Workflow - The partnership offers a streamlined sampling and testing workflow, enabling healthcare facilities to monitor contamination effectively and take timely actions to protect workers [2]. - The combined testing approach aligns with recommendations from a 2020 consensus conference on hazardous drug surface contamination, advocating for both qualitative and quantitative testing to enhance environmental safety [2].

Core Insights - BD (Becton, Dickinson and Company) has launched new configurations of the BD FACSDiscover™ A8 Cell Analyzers, enhancing accessibility to advanced spectral and real-time imaging technologies for various laboratories [1] - The new analyzers allow scientists to analyze over 50 characteristics of a single cell with high resolution and sensitivity, facilitating discoveries in immunology, cancer immunotherapy, and cell biology [1] - The introduction of three- and four-laser configurations complements the previously launched five-laser model, broadening the technology's reach to more labs globally [1] Product Features - BD SpectralFX™ Technology enables detailed analysis of single cells, while BD CellView™ Image Technology provides high-speed imaging for real-time spatial and morphological insights [1] - The analyzers feature high-throughput, walkaway automation, optimizing cost-per-insight economics through real-time imaging [1] - Intuitive software is designed for managing large datasets and standardization, enhancing user experience [1] Market Impact - The BD FACSDiscover™ A8 Cell Analyzer is rapidly being adopted by leading biopharmaceutical companies, with flexible financing options available for organizations facing capital expenditure constraints [1] - The technology is positioned to support a wide range of research needs, from basic to translational science, making it accessible to labs of all sizes [1] - BD continues to expand its ecosystem with new fluorochromes, such as BD Horizon RealViolet™ 828 and RealBlue™ 824, which enhance spectral flow cytometry capabilities [1]

Core Insights - Becton, Dickinson and Company (BDX) is a leading player in the medical supplies and devices sector, with a market capitalization of $55.4 billion, focusing on advancing medical research, diagnostics, and infection prevention [1][2] Company Overview - BDX is categorized as a large-cap stock, reflecting its significant size and influence in the medical instruments and supplies industry [2] - The company boasts a strong global brand, extensive distribution network, and a diverse product portfolio, which are key to its competitive advantage [2] - BDX's growth is driven by its commitment to innovation, substantial R&D investments, and strategic acquisitions, alongside a robust manufacturing and supply chain [2] Stock Performance - BDX's stock has experienced a decline of 23% from its 52-week high of $251.99, reached on February 3 [3] - Over the past three months, BDX's stock gained 1.5%, underperforming the Nasdaq Composite, which saw a 7.7% increase [3] - Year-to-date, BDX shares have fallen 14.5%, and over the past 52 weeks, they have decreased by 12.6%, significantly lagging behind the Nasdaq's YTD gains of 21% and 22.6% [4] Recent Financial Performance - In its Q4 results, BDX reported an adjusted EPS of $3.96, surpassing Wall Street's expectations of $3.92, with revenue of $5.9 billion meeting forecasts [5] - The company anticipates full-year adjusted EPS to be in the range of $14.75 to $15.05 [5] Competitive Landscape - BDX's competitor, Solventum Corporation (SOLV), has outperformed BDX, with a 17.6% gain over the past 52 weeks and a 29.1% increase year-to-date [6]

Acquisitions and Mergers - BD completed the acquisition of Edwards Lifesciences' Critical Care product group for a fair value of $3.914 billion, now reported as BD Advanced Patient Monitoring[18]. - BD entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation, expecting to receive approximately $4 billion in cash distribution prior to completion[19]. - BD's shareholders are expected to own approximately 39.2% of the combined company post-transaction with Waters Corporation[19]. - The proposed combination with Waters is expected to result in shareholders owning approximately 39.2% of the combined company, pending regulatory approvals[127]. - The transaction with Waters is anticipated to close around the end of Q1 2026, but completion is not guaranteed[127]. - The spin-off of Embecta Corp. was completed on April 1, 2022, and is intended to be tax-free; however, any failure to meet conditions could result in tax liabilities[130][131]. Financial Performance - Worldwide revenues in 2025 reached $21.840 billion, an increase of 8.2% from the prior year, driven by a 4.8% contribution from the acquisition of Advanced Patient Monitoring[182]. - Cash flows from continuing operating activities were $3.430 billion in 2025, with $859 million in cash and equivalents at the end of the fiscal year[182]. - The Medical segment reported total revenues of $11.456 billion in 2025, reflecting a 13.7% increase compared to 2024[186]. - The Advanced Patient Monitoring unit, acquired in September 2024, generated $1.082 billion in revenue in 2025, significantly contributing to the Medical segment's growth[186]. - The Medication Management Solutions unit experienced a revenue increase of 5.4% in 2025, driven by strong sales of infusion systems[186]. - Medical segment operating income for 2025 was $4,140 million, representing a 15.5% increase from $3,583 million in 2024, with an operating income margin of 36.1%[190]. - Life Sciences segment revenues totaled $5,167 million in 2025, a slight decline of 0.5% compared to $5,191 million in 2024, with a segment operating income of $1,641 million, or 31.8% of revenues[191][193]. - Interventional segment revenues increased by 4.8% to $5,217 million in 2025, with operating income rising to $2,253 million, reflecting a margin of 43.2%[196][198]. - U.S. revenues reached $12,790 million in 2025, a 9.7% increase from $11,663 million in 2024, largely driven by the Advanced Patient Monitoring unit's sales[199]. - International revenues grew by 6.3% to $9,049 million in 2025, supported by strong sales across all Interventional segment units[201]. - Emerging market revenues increased by 2.6% to $3,133 million in 2025, with strong sales in Greater Asia and Latin America, despite declines in China[205]. Regulatory and Compliance Issues - BD's operations are subject to increasing regulatory scrutiny from agencies like the FDA, affecting product development and market availability[34]. - The FDA issued a non-compliance letter to CareFusion 303, Inc. regarding quality system issues, requiring a comprehensive corrective action plan[40]. - Increased regulation on ethylene oxide emissions may impact BD's sterilization operations and lead to additional costs[48]. - The company is facing potential penalties of $15,000 per day for violations of the Consent Decree, with a maximum of $15 million per year[42]. - The company has business continuity plans to mitigate potential disruptions in sterilization operations, although these may not fully offset impacts[50]. - The FDA has issued warning letters affecting the BD Alaris™ infusion pump business, necessitating compliance and remediation efforts[114]. - The company received FDA 510(k) clearance for the updated BD Alaris™ Infusion System, with remediation expected to be substantially complete over the next calendar year[115]. - The European Union's Medical Device Regulation (EU MDR) and In Vitro Diagnostic Regulation (EU IVDR) impose stricter requirements, with compliance costs expected to be significant[116]. - The EU MDR is fully applicable since May 2021, with extended application until 2027 for higher-risk devices and 2028 for others[116]. - Increased regulation may necessitate temporary suspensions of sterilization operations, impacting production capacity and potentially leading to civil litigation[102]. - The company faces extensive regulatory scrutiny, which may increase compliance costs and impact financial performance[110]. Research and Development - BD's R&D activities are primarily conducted in North America, with significant presences in Greater Asia and Europe, collaborating with universities and medical centers[27]. - Research and development expenses as a percentage of revenues increased in 2025, primarily due to costs associated with the Advanced Patient Monitoring unit[192]. - The company’s future growth relies on successful new product development, which requires substantial investment in R&D and regulatory approvals[83]. Market and Competitive Landscape - The company faces increased pricing pressures due to the entry of low-cost manufacturers in the medical technology market[29]. - The medical technology industry is highly competitive, with significant competition from both established companies and new entrants, including technology firms[76]. - Changing customer preferences and regulatory demands require BD to adapt its product offerings and market strategies to remain competitive[77]. - Rapid technological changes in the industry necessitate continuous innovation to prevent product obsolescence[78]. - The medical technology industry is experiencing significant consolidation, increasing competition and downward pricing pressure for medical device suppliers[79]. - Changes in reimbursement practices and healthcare funding could adversely affect demand and pricing for the company's products[80]. - The proposed expansion of the Competitive Bidding Program by the Center for Medicaid Services could significantly influence the cost structure of certain medical devices in the U.S.[81]. - A reduction in government funding for research and development has been observed, impacting customer spending and potentially affecting the company's sales[82]. Operational Challenges - The company faces risks from global economic conditions, including inflation and supply chain disruptions, which could impact demand for products[68]. - Supply chain disruptions and reliance on sole suppliers for certain raw materials could negatively impact manufacturing and sales[96]. - The company is integrating AI into its products and operations, which presents various regulatory and operational challenges[94]. - The competitive labor market poses challenges in attracting and retaining skilled employees, potentially increasing operational costs[86]. - The company has manufacturing operations worldwide, but interruptions due to various factors could adversely affect product manufacturing and lead to lost revenues[98]. - Many products require sterilization, and limited capacity at qualified facilities could impact the ability to sterilize products, affecting operating results and financial condition[99]. - Cost volatility in raw materials, particularly resin, could negatively impact future operating results, despite cost containment measures[103]. - Climate change and related regulations may increase operational costs and affect supply chain availability, impacting business operations[104]. Employee Engagement and Corporate Culture - BD employs approximately 72,000 associates across 61 countries as of September 30, 2025[52]. - The company has reintroduced performance ratings and calibration in 2025 to enhance performance differentiation and align rewards with individual contributions[53]. - BD University provides all associates access to internal learning resources aimed at developing core and management capabilities[55]. - The total rewards program includes market-competitive pay, stock grants, bonuses, healthcare benefits, and flexible work schedules to support associate well-being[56]. - BD was recognized as one of America's Most Innovative Companies by Fortune and received the "Best Employers: Excellence in Health & Well-being Award" from the Business Group on Health in 2025[61]. Cybersecurity - BD achieved ISO/IEC 27001:2022 certification in 2022, demonstrating compliance with internationally recognized cybersecurity standards[140]. - The company has a comprehensive cybersecurity risk management program guided by the NIST Cybersecurity Framework 2.0, focusing on protecting BD products and data[138]. - BD's Chief Information Security Officer (CISO) leads the cybersecurity risk management program, supported by a team with over 20 years of experience in information security[145]. - The company has engaged third-party auditors for annual surveillance audits to ensure compliance with cybersecurity standards, with the latest audit confirming ongoing adherence[140]. - BD's cybersecurity program includes mandatory quarterly training for associates and contractors, along with monthly phishing simulations to enhance awareness[139]. - The company actively monitors third-party cybersecurity risks throughout the procurement lifecycle, including assessments and remediation measures[142].

Core Insights - BD (Becton, Dickinson and Company) has launched the BD Surgiphor™ Surgical Wound Irrigation System in Europe, marking a significant advancement in surgical care and patient safety [1][2][3] Product Overview - The BD Surgiphor™ is a sterile, ready-to-use irrigation solution designed to remove debris from surgical wounds, thereby reducing the bacterial load that can lead to infections [2][5] - This system is the first of its kind to receive Conformité Européenne (CE) approval and is now available in select European countries [1][2] Impact on Healthcare - The introduction of Surgiphor™ aims to support clinicians in implementing evidence-based practices to reduce surgical site infections, which are a major challenge for patient outcomes and healthcare systems [3] - By simplifying the irrigation process and reducing preparation time, the system enhances hospital efficiency and improves patient safety [3][5] Company Commitment - BD emphasizes its commitment to advancing surgical care through practical solutions that prioritize patient safety [3] - The company operates globally, with over 70,000 employees dedicated to improving healthcare delivery and outcomes [4]

Core Insights - Cullen Capital Management's "SCCM Value Equity Strategy" reported a gross return of 6.9% and a net return of 6.8% for Q3 2025, outperforming the Russell 1000 Value's 5.3% and underperforming the S&P 500's 8.1% during the same period [1] - Year-to-date, the strategy achieved a gross return of 13.0%, compared to Russell 1000 Value's 11.7% and S&P 500's 14.8% [1] Company Overview - Becton, Dickinson and Company (NYSE: BDX) is a global medical technology company that develops and manufactures a wide range of medical supplies, devices, laboratory equipment, and diagnostic products [2][3] - The company has three main segments: BD Medical (50% of 2024 sales), BD Life Sciences (26%), and BD Interventional (24%) [3] - BD Medical focuses on medication delivery devices, holding over 80% market share in US hospital syringes, making it the largest manufacturer of syringes globally [3] Stock Performance - Becton, Dickinson and Company's stock had a one-month return of 2.24% but lost 13.52% over the last 52 weeks, closing at $192.33 per share on November 18, 2025, with a market capitalization of $55.127 billion [2]

Core Insights - 1578 Partners outperformed the S&P 500 index in Q3, achieving a return of 14.37% compared to the index's 13.93% [1] Company Performance - 1578 Partners serves as the model account for taxable accounts managed by Hinde Group [1]